{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:07:27Z","timestamp":1786622847985,"version":"build-2736575974"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005869","name":"University of Fribourg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Peripheral levels of brain-derived neurotrophic factor (BDNF) are often used as a biomarker for the rapid plasticity-promoting effects of ketamine, psychedelics, and other psychoplastogens in humans. However, studies analyzing peripheral BDNF after psychoplastogen exposure show mixed results. In this meta-analysis, we aimed to test whether the rapid upregulation of neuroplasticity seen in preclinical studies is detectable using peripheral BDNF in humans.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This analysis was pre-registered (PROSPERO ID: CRD42022333096) and funded by the University of Fribourg. We systematically searched PubMed, Web of Science, and PsycINFO to meta-analyze the effects of all available psychoplastogens on peripheral BDNF levels in humans, including ketamine, esketamine, LSD, psilocybin, ayahuasca, DMT, MDMA, scopolamine, and rapastinel. Risk of bias was assessed using Cochrane Risk of Bias Tools. Using meta-regressions and mixed effects models, we additionally analyzed the impact of several potential moderators.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We included 29 studies and found no evidence that psychoplastogens elevate peripheral BDNF levels in humans (SMD\u2009=\u20090.024, <jats:italic>p<\/jats:italic>\u2009=\u20090.64). This result was not affected by drug, dose, blood fraction, participant age, or psychiatric diagnoses. In general, studies with better-controlled designs and fewer missing values reported smaller effect sizes. Later measurement timepoints showed minimally larger effects on BDNF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These data suggest that peripheral BDNF levels do not change after psychoplastogen administration in humans. It is possible that peripheral BDNF is not an informative marker of rapid changes in neuroplasticity, or that preclinical findings on psychoplastogens and neuroplasticity may not translate to human subjects. Limitations of this analysis include the reliability and validity of BDNF measurement and low variation in some potential moderators. More precise methods of measuring rapid changes in neuroplasticity, including neuroimaging and stimulation-based methods, are recommended for future studies attempting to translate preclinical findings to humans.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41380-024-02830-z","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T09:18:53Z","timestamp":1732871933000},"page":"763-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-404X","authenticated-orcid":false,"given":"Abigail E.","family":"Calder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Hase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8311-0138","authenticated-orcid":false,"given":"Gregor","family":"Hasler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"2830_CR1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"2830_CR2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959\u201364.","journal-title":"Science"},{"key":"2830_CR3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41380-019-0615-x","volume":"25","author":"RB Price","year":"2020","unstructured":"Price RB, Duman R. Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model. Mol Psychiatry. 2020;25:530\u201343.","journal-title":"Mol Psychiatry"},{"key":"2830_CR4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4306\/pi.2010.7.4.243","volume":"7","author":"I Grande","year":"2010","unstructured":"Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig. 2010;7:243\u201350.","journal-title":"Psychiatry Investig"},{"key":"2830_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/2045125316638008","volume":"6","author":"RG Dos Santos","year":"2016","unstructured":"Dos Santos RG, Osorio FL, Crippa JA, Riba J, Zuardi AW, Hallak JE. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol. 2016;6:193\u2013213.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2830_CR6","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"2830_CR7","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"Moliner R","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341.","journal-title":"Nat Neurosci"},{"key":"2830_CR8","doi-asserted-by":"crossref","unstructured":"Jefferson SJ, Gregg I, Dibbs M, Liao C, Wu H, Davoudian PA, et al. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology. 2023;48:1257\u201366.","DOI":"10.1038\/s41386-023-01572-w"},{"key":"2830_CR9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700\u20136.","journal-title":"Science"},{"key":"2830_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1021\/acs.biochem.1c00812","volume":"61","author":"DE Olson","year":"2022","unstructured":"Olson DE. Biochemical mechanisms underlying psychedelic-induced neuroplasticity. Biochemistry. 2022;61:127\u201336.","journal-title":"Biochemistry"},{"key":"2830_CR11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48:104\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"2830_CR12","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/mp.2017.61","volume":"22","author":"E Castren","year":"2017","unstructured":"Castren E, Antila H. Neuronal plasticity and neurotrophic factors in drug responses. Mol Psychiatry. 2017;22:1085\u201395.","journal-title":"Mol Psychiatry"},{"key":"2830_CR13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1124\/pr.115.010967","volume":"67","author":"ER Korpi","year":"2015","unstructured":"Korpi ER, den Hollander B, Farooq U, Vashchinkina E, Rajkumar R, Nutt DJ, et al. Mechanisms of action and persistent neuroplasticity by drugs of abuse. Pharmacol Rev. 2015;67:872\u20131004.","journal-title":"Pharmacol Rev"},{"key":"2830_CR14","doi-asserted-by":"crossref","unstructured":"Olson DE. Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci. 2018;12: 1179069518800508.","DOI":"10.1177\/1179069518800508"},{"key":"2830_CR15","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"LX Shao","year":"2021","unstructured":"Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535\u201344.e2534.","journal-title":"Neuron"},{"key":"2830_CR16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1021\/acsptsci.0c00065","volume":"4","author":"C Ly","year":"2021","unstructured":"Ly C, Greb AC, Vargas MV, Duim WC, Grodzki ACG, Lein PJ, et al. Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth. Acs Pharmacol Transl Sci. 2021;4:452\u201360.","journal-title":"Acs Pharmacol Transl Sci"},{"key":"2830_CR17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/npp.2016.202","volume":"42","author":"RJ Liu","year":"2017","unstructured":"Liu RJ, Duman C, Kato T, Hare B, Lopresto D, Bang E, et al. GLYX-13 produces rapid antidepressant responses with key synaptic and behavioral effects distinct from ketamine. Neuropsychopharmacology. 2017;42:1231\u201342.","journal-title":"Neuropsychopharmacology"},{"key":"2830_CR18","doi-asserted-by":"crossref","unstructured":"Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, et al. 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chem Neurosci. 2023;1:351\u20138.","DOI":"10.1021\/acschemneuro.2c00718"},{"key":"2830_CR19","doi-asserted-by":"crossref","unstructured":"Du Y, Li Y, Zhao X, Yao Y, Wang B, Zhang L, et al. Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity. Chin Med J (Engl). 2023;136:2983\u201392.","DOI":"10.1097\/CM9.0000000000002647"},{"key":"2830_CR20","doi-asserted-by":"crossref","unstructured":"Nardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, de Deus JL, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;18:790\u20138.","DOI":"10.1038\/s41586-023-06204-3"},{"key":"2830_CR21","doi-asserted-by":"crossref","unstructured":"Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and other psychoplastogens for treating mental illness. Front Psychiatry. 2021;12:727117.","DOI":"10.3389\/fpsyt.2021.727117"},{"key":"2830_CR22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/13651501003748560","volume":"14","author":"R Yoshimura","year":"2010","unstructured":"Yoshimura R, Sugita-Ikenouchi A, Hori H, Umene-Nakano W, Hayashi K, Katsuki A, et al. A close correlation between plasma and serum levels of brain-derived neurotrophic factor (BDNF) in healthy volunteers. Int J Psychiatry Clin Pract. 2010;14:220\u20132.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2830_CR23","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.214","volume":"6","author":"A Cattaneo","year":"2016","unstructured":"Cattaneo A, Cattane N, Begni V, Pariante CM, Riva MA. The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders. Transl Psychiatry. 2016;6:e958.","journal-title":"Transl Psychiatry"},{"key":"2830_CR24","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0000000000001507","volume":"84","author":"EE Benarroch","year":"2015","unstructured":"Benarroch EE. Brain-derived neurotrophic factor: regulation, effects, and potential clinical relevance. Neurology. 2015;84:1693\u2013704.","journal-title":"Neurology"},{"key":"2830_CR25","doi-asserted-by":"crossref","unstructured":"Wang CS, Kavalali ET, Monteggia LM. BDNF signaling in context: from synaptic regulation to psychiatric disorders. Cell. 2021.","DOI":"10.1016\/j.cell.2021.12.003"},{"key":"2830_CR26","doi-asserted-by":"crossref","unstructured":"Arosio B, Guerini FR, Voshaar RCO, Aprahamian I. Blood brain-derived neurotrophic factor (BDNF) and major depression: do we have a translational perspective? Front Behav Neurosci. 2021;15:626906.","DOI":"10.3389\/fnbeh.2021.626906"},{"key":"2830_CR27","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.1074\/jbc.M116.720029","volume":"291","author":"P Chacon-Fernandez","year":"2016","unstructured":"Chacon-Fernandez P, Sauberli K, Colzani M, Moreau T, Ghevaert C, Barde YA. Brain-derived neurotrophic factor in megakaryocytes. J Biol Chem. 2016;291:9872\u201381.","journal-title":"J Biol Chem"},{"key":"2830_CR28","doi-asserted-by":"crossref","unstructured":"Josefsson EC, Vainchenker W, James C. Regulation of platelet production and life span: role of Bcl-xL and potential implications for human platelet diseases. Int J Mol Sci. 2020;21:7591.","DOI":"10.3390\/ijms21207591"},{"key":"2830_CR29","volume":"6","author":"ST Muller","year":"2020","unstructured":"Muller ST, Buchmann A, Haynes M, Ghisleni C, Ritter C, Tuura R, et al. Negative association between left prefrontal GABA concentration and BDNF serum concentration in young adults. Heliyon. 2020;6:e04025.","journal-title":"Heliyon"},{"key":"2830_CR30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00441-020-03253-2","volume":"382","author":"T Brigadski","year":"2020","unstructured":"Brigadski T, Lessmann V. The physiology of regulated BDNF release. Cell Tissue Res. 2020;382:15\u201345.","journal-title":"Cell Tissue Res"},{"key":"2830_CR31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrd3366","volume":"10","author":"AH Nagahara","year":"2011","unstructured":"Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10:209\u201319.","journal-title":"Nat Rev Drug Discov"},{"key":"2830_CR32","doi-asserted-by":"crossref","first-page":"e62241","DOI":"10.1371\/journal.pone.0062241","volume":"8","author":"S Pilakka-Kanthikeel","year":"2013","unstructured":"Pilakka-Kanthikeel S, Atluri VS, Sagar V, Saxena SK, Nair M. Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study. PLoS One. 2013;8:e62241.","journal-title":"PLoS One"},{"key":"2830_CR33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.psyneuen.2010.07.013","volume":"36","author":"BA Bus","year":"2011","unstructured":"Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J, et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology. 2011;36:228\u201339.","journal-title":"Psychoneuroendocrinology"},{"key":"2830_CR34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/07853890.2015.1131327","volume":"48","author":"K Schmitt","year":"2016","unstructured":"Schmitt K, Holsboer-Trachsler E, Eckert A. BDNF in sleep, insomnia, and sleep deprivation. Ann Med. 2016;48:42\u201351.","journal-title":"Ann Med"},{"key":"2830_CR35","doi-asserted-by":"crossref","DOI":"10.1038\/srep17989","volume":"5","author":"A Polacchini","year":"2015","unstructured":"Polacchini A, Metelli G, Francavilla R, Baj G, Florean M, Mascaretti LG, et al. A method for reproducible measurements of serum BDNF: comparison of the performance of six commercial assays. Sci Rep. 2015;5:17989.","journal-title":"Sci Rep"},{"key":"2830_CR36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/15622975.2011.562244","volume":"12","author":"MK Brandys","year":"2011","unstructured":"Brandys MK, Kas MJ, Van Elburg AA, Campbell IC, Adan RA. A metaanalysis of circulating BDNF concentrations in anorexia nervosa. The World Journal of Biological Psychiatry. 2011;12:444\u201354.","journal-title":"The World Journal of Biological Psychiatry"},{"key":"2830_CR37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000388814","volume":"7","author":"S Suliman","year":"2013","unstructured":"Suliman S, Hemmings SM, Seedat S. Brain-Derived Neurotrophic Factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis. Front Integr Neurosci. 2013;7:55.","journal-title":"Front Integr Neurosci"},{"key":"2830_CR38","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03312-y","volume":"20","author":"H Mojtabavi","year":"2022","unstructured":"Mojtabavi H, Shaka Z, Momtazmanesh S, Ajdari A, Rezaei N. Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis. J Transl Med. 2022;20:126.","journal-title":"J Transl Med"},{"key":"2830_CR39","doi-asserted-by":"crossref","unstructured":"Ng TKS, Ho CSH, Tam WWS, Kua EH, Ho RC. Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer\u2019s disease (AD): a systematic review and meta-analysis. Int J Mol Sci. 2019;20:257.","DOI":"10.3390\/ijms20020257"},{"key":"2830_CR40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pnpbp.2018.07.010","volume":"88","author":"L Jiang","year":"2019","unstructured":"Jiang L, Zhang H, Wang C, Ming F, Shi X, Yang M. Serum level of brain-derived neurotrophic factor in Parkinson\u2019s disease: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2019;88:168\u201374.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2830_CR41","doi-asserted-by":"crossref","first-page":"e0163037","DOI":"10.1371\/journal.pone.0163037","volume":"11","author":"A Dinoff","year":"2016","unstructured":"Dinoff A, Herrmann N, Swardfager W, Liu CS, Sherman C, Chan S, et al. The effect of exercise training on resting concentrations of peripheral brain-derived neurotrophic factor (BDNF): a meta-analysis. PLoS One. 2016;11:e0163037.","journal-title":"PLoS One"},{"key":"2830_CR42","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.561464","volume":"11","author":"G Hasler","year":"2020","unstructured":"Hasler G, Haynes M, Muller ST, Tuura R, Ritter C, Buchmann A. The association between adolescent residential mobility and adult social anxiety, BDNF and amygdala-orbitofrontal functional connectivity in young adults with higher education. Front Psychiatry. 2020;11:561464.","journal-title":"Front Psychiatry"},{"key":"2830_CR43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3109\/15622971003611319","volume":"11","author":"L Bocchio-Chiavetto","year":"2010","unstructured":"Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry. 2010;11:763\u201373.","journal-title":"World J Biol Psychiatry"},{"key":"2830_CR44","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mp.2013.105","volume":"19","author":"ML Molendijk","year":"2014","unstructured":"Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry. 2014;19:791\u2013800.","journal-title":"Mol Psychiatry"},{"key":"2830_CR45","doi-asserted-by":"crossref","unstructured":"Homan P, Grob S, Milos G, Schnyder U, Eckert A, Lang U, et al. The role of BDNF, leptin, and catecholamines in reward learning in bulimia nervosa. Int J Neuropsychopharmacol. 2014;18:pyu092.","DOI":"10.1093\/ijnp\/pyu092"},{"key":"2830_CR46","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1017\/S1461145708009309","volume":"11","author":"AR Brunoni","year":"2008","unstructured":"Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008;11:1169\u201380.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2830_CR47","doi-asserted-by":"crossref","first-page":"e0172270","DOI":"10.1371\/journal.pone.0172270","volume":"12","author":"C Zhou","year":"2017","unstructured":"Zhou C, Zhong J, Zou B, Fang L, Chen J, Deng X, et al. Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression. PLoS One. 2017;12:e0172270.","journal-title":"PLoS One"},{"key":"2830_CR48","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jad.2014.11.044","volume":"174","author":"M Polyakova","year":"2015","unstructured":"Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord. 2015;174:432\u201340.","journal-title":"J Affect Disord"},{"key":"2830_CR49","doi-asserted-by":"crossref","first-page":"114857","DOI":"10.1016\/j.psychres.2022.114857","volume":"317","author":"S Meshkat","year":"2022","unstructured":"Meshkat S, Alnefeesi Y, Jawad MY, DDV J, BR N, Ceban F, et al. Brain-derived neurotrophic factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): a systematic review & meta-analysis. Psychiatry Res. 2022;317:114857.","journal-title":"Psychiatry Res"},{"key":"2830_CR50","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1038\/s41380-022-01652-1","volume":"27","author":"GC Medeiros","year":"2022","unstructured":"Medeiros GC, Gould TD, Prueitt WL, Nanavati J, Grunebaum MF, Farber NB, et al. Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. Mol Psychiatry. 2022;27:3658\u201369.","journal-title":"Mol Psychiatry"},{"key":"2830_CR51","doi-asserted-by":"crossref","unstructured":"Lopez-Lopez JA, Page MJ, Lipsey MW, Higgins JPT. Dealing with effect size multiplicity in systematic reviews and meta-analyses. Res Synth Methods. 2018.","DOI":"10.1002\/jrsm.1310"},{"key":"2830_CR52","doi-asserted-by":"crossref","unstructured":"Shafiee A, Arabzadeh Bahri R, Rafiei MA, Esmaeilpur Abianeh F, Razmara P, Jafarabady K, et al. The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis. J Psychopharmacol. 2024: 2698811241234247.","DOI":"10.1177\/02698811241234247"},{"key":"2830_CR53","unstructured":"Calder A, Hase A. The effects of psychoplastogens on peripheral BDNF in humans. PROSPERO: International prospective register of systematic reviews 2022."},{"key":"2830_CR54","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2830_CR55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/j.1460-2075.1982.tb01207.x","volume":"1","author":"YA Barde","year":"1982","unstructured":"Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1:549\u201353.","journal-title":"EMBO J"},{"key":"2830_CR56","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"2830_CR57","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"2830_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"2830_CR59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"2830_CR60","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze F, Vizeli P, Muller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 2020;45:462\u201371.","journal-title":"Neuropsychopharmacology"},{"key":"2830_CR61","doi-asserted-by":"crossref","unstructured":"Straumann I, Ley L, Holze F, Becker AM, Klaiber A, Wey K, et al. Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacology. 2023;48:1840\u20138.","DOI":"10.1038\/s41386-023-01609-0"},{"key":"2830_CR62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ijnp\/pyac075","volume":"26","author":"AM Becker","year":"2023","unstructured":"Becker AM, Klaiber A, Holze F, Istampoulouoglou I, Duthaler U, Varghese N, et al. Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants. Int J Neuropsychopharmacol. 2023;26:97\u2013106.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2830_CR63","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acsptsci.0c00099","volume":"4","author":"N Hutten","year":"2021","unstructured":"Hutten N, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, et al. Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. ACS Pharmacol Transl Sci. 2021;4:461\u20136.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2830_CR64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1017\/neu.2021.17","volume":"33","author":"L Manarte","year":"2021","unstructured":"Manarte L, Saldanha J, Andrade AR, Tanqueiro S, Morgado P, Sahakian BJ. Plasma BDNF and insight in OCD: a promising path for future research. Acta Neuropsychiatr. 2021;33:277\u20139.","journal-title":"Acta Neuropsychiatr"},{"key":"2830_CR65","doi-asserted-by":"crossref","unstructured":"Polyakova M, Schlogl H, Sacher J, Schmidt-Kassow M, Kaiser J, Stumvoll M, et al. Stability of BDNF in human samples stored up to 6 months and correlations of serum and EDTA-plasma concentrations. Int J Mol Sci. 2017;18:1189.","DOI":"10.3390\/ijms18061189"},{"key":"2830_CR66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5498\/wjp.v12.i3.379","volume":"12","author":"XP Zhao","year":"2022","unstructured":"Zhao XP, Li H, Dai RP. Neuroimmune crosstalk through brain-derived neurotrophic factor and its precursor pro-BDNF: new insights into mood disorders. World J Psychiatry. 2022;12:379\u201392.","journal-title":"World J Psychiatry"},{"key":"2830_CR67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5498\/wjp.v6.i1.84","volume":"6","author":"M Serra-Millas","year":"2016","unstructured":"Serra-Millas M. Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation? World J Psychiatry. 2016;6:84\u2013101.","journal-title":"World J Psychiatry"},{"key":"2830_CR68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S1461145710000738","volume":"14","author":"AB Klein","year":"2011","unstructured":"Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14:347\u201353.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2830_CR69","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jpsychires.2006.01.014","volume":"41","author":"C Laske","year":"2007","unstructured":"Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, et al. BDNF serum and CSF concentrations in Alzheimer\u2019s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res. 2007;41:387\u201394.","journal-title":"J Psychiatr Res"},{"key":"2830_CR70","doi-asserted-by":"crossref","first-page":"e39358","DOI":"10.1371\/journal.pone.0039358","volume":"7","author":"A Pillai","year":"2012","unstructured":"Pillai A, Bruno D, Sarreal AS, Hernando RT, Saint-Louis LA, Nierenberg J, et al. Plasma BDNF levels vary in relation to body weight in females. PLoS One. 2012;7:e39358.","journal-title":"PLoS One"},{"key":"2830_CR71","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s13346-017-0476-2","volume":"8","author":"M Le Nedelec","year":"2018","unstructured":"Le Nedelec M, Glue P, Winter H, Goulton C, Broughton L, Medlicott N. Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations. Drug Deliv Transl Res. 2018;8:780\u20136.","journal-title":"Drug Deliv Transl Res"},{"key":"2830_CR72","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3109\/1354750X.2012.694476","volume":"17","author":"TA Lanz","year":"2012","unstructured":"Lanz TA, Bove SE, Pilsmaker CD, Mariga A, Drummond EM, Cadelina GW, et al. Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma. Biomarkers. 2012;17:524\u201331.","journal-title":"Biomarkers"},{"key":"2830_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145709991039","volume":"13","author":"P Gass","year":"2010","unstructured":"Gass P, Hellweg R. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker for affective disorders? Int J Neuropsychopharmacol. 2010;13:1\u20134.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2830_CR74","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1073858418810142","volume":"25","author":"M Notaras","year":"2019","unstructured":"Notaras M, van den Buuse M. Brain-derived neurotrophic factor (BDNF): novel insights into regulation and genetic variation. Neuroscientist. 2019;25:434\u201354.","journal-title":"Neuroscientist"},{"key":"2830_CR75","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrn1970","volume":"7","author":"J Nithianantharajah","year":"2006","unstructured":"Nithianantharajah J, Hannan AJ. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci. 2006;7:697\u2013709.","journal-title":"Nat Rev Neurosci"},{"key":"2830_CR76","doi-asserted-by":"crossref","first-page":"e53888","DOI":"10.1371\/journal.pone.0053888","volume":"8","author":"RP Fares","year":"2013","unstructured":"Fares RP, Belmeguenai A, Sanchez PE, Kouchi HY, Bodennec J, Morales A, et al. Standardized environmental enrichment supports enhanced brain plasticity in healthy rats and prevents cognitive impairment in epileptic rats. PLoS One. 2013;8:e53888.","journal-title":"PLoS One"},{"key":"2830_CR77","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ana.10262","volume":"52","author":"G Kempermann","year":"2002","unstructured":"Kempermann G, Gast D, Gage FH. Neuroplasticity in old age: sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol. 2002;52:135\u201343.","journal-title":"Ann Neurol"},{"key":"2830_CR78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ddtec.2017.11.003","volume":"25","author":"J Mercier","year":"2017","unstructured":"Mercier J, Provins L, Valade A. Discovery and development of SV2A PET tracers: potential for imaging synaptic density and clinical applications. Drug Discov Today Technol. 2017;25:45\u201352.","journal-title":"Drug Discov Today Technol"},{"key":"2830_CR79","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-021-01318-6","volume":"11","author":"A H\u00f6flich","year":"2021","unstructured":"H\u00f6flich A, Kraus C, Pfeiffer RM, Seiger R, Rujescu D, Zarate CA Jr, et al. Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial. Transl Psychiatry. 2021;11:200.","journal-title":"Transl Psychiatry"},{"key":"2830_CR80","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/npp.2017.49","volume":"42","author":"CG Abdallah","year":"2017","unstructured":"Abdallah CG, Jackowski A, Salas R, Gupta S, Sato JR, Mao X, et al. The nucleus accumbens and ketamine treatment in major depressive disorder. Neuropsychopharmacology. 2017;42:1739\u201346.","journal-title":"Neuropsychopharmacology"},{"key":"2830_CR81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41398-020-0692-2","volume":"10","author":"YL Zhou","year":"2020","unstructured":"Zhou YL, Wu FC, Liu WJ, Zheng W, Wang CY, Zhan YN, et al. Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder: a longitudinal analysis. Transl Psychiatr. 2020;10:9.","journal-title":"Transl Psychiatr"},{"key":"2830_CR82","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pscychresns.2021.111369","volume":"317","author":"CC Gallay","year":"2021","unstructured":"Gallay CC, Forsyth G, Can AT, Dutton M, Jamieson D, Jensen E, et al. Six-week oral ketamine treatment for chronic suicidality is associated with increased grey matter volume. Psychiatry Res Neuroimaging. 2021;317:4.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"2830_CR83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.euroneuro.2020.11.017","volume":"43","author":"A Herrera-Melendez","year":"2021","unstructured":"Herrera-Melendez A, Stippl A, Aust S, Scheidegger M, Seifritz E, Heuser-Collier I, et al. Gray matter volume of rostral anterior cingulate cortex predicts rapid antidepressant response to ketamine. Eur Neuropsychopharmacol. 2021;43:63\u201370.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2830_CR84","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuroimage.2016.12.032","volume":"147","author":"A Hoflich","year":"2017","unstructured":"Hoflich A, Ganger S, Tik M, Hahn A, Kranz GS, Vanicek T, et al. Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control. Neuroimage. 2017;147:198\u2013203.","journal-title":"Neuroimage"},{"key":"2830_CR85","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-023-02451-0","volume":"13","author":"J Kopelman","year":"2023","unstructured":"Kopelman J, Keller TA, Panny B, Griffo A, Degutis M, Spotts C, et al. Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression. Transl Psychiatry. 2023;13:159.","journal-title":"Transl Psychiatry"},{"key":"2830_CR86","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2215-0366(23)00183-9","volume":"10","author":"GC Medeiros","year":"2023","unstructured":"Medeiros GC, Matheson M, Demo I, Reid MJ, Matheson S, Twose C, et al. Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies. Lancet Psychiatry. 2023;10:790\u2013800.","journal-title":"Lancet Psychiatry"},{"key":"2830_CR87","doi-asserted-by":"crossref","unstructured":"Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, et al. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Mol Psychiatry. 2022;27:2273\u201381.","DOI":"10.1038\/s41380-022-01465-2"},{"key":"2830_CR88","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11065-014-9252-y","volume":"24","author":"C Kelly","year":"2014","unstructured":"Kelly C, Castellanos FX. Strengthening connections: functional connectivity and brain plasticity. Neuropsychol Rev. 2014;24:63\u201376.","journal-title":"Neuropsychol Rev"},{"key":"2830_CR89","doi-asserted-by":"crossref","unstructured":"Stampanoni Bassi M, Iezzi E, Gilio L, Centonze D, Buttari F. Synaptic plasticity shapes brain connectivity: implications for network topology. Int J Mol Sci. 2019;20:6193.","DOI":"10.3390\/ijms20246193"},{"key":"2830_CR90","volume":"10","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10:2214.","journal-title":"Sci Rep"},{"key":"2830_CR91","doi-asserted-by":"crossref","unstructured":"McCulloch DE, Madsen MK, Stenbaek DS, Kristiansen S, Ozenne B, Jensen PS, et al. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. J Psychopharmacol. 2021: 2698811211026454.","DOI":"10.1101\/2021.01.28.428377"},{"key":"2830_CR92","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ijnp\/pyx036","volume":"20","author":"F Sampedro","year":"2017","unstructured":"Sampedro F, de la Fuente Revenga M, Valle M, Roberto N, Dominguez-Clave E, Elices M, et al. Assessing the psychedelic \u201cafter-glow\u201d in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. Int J Neuropsychopharmacol. 2017;20:698\u2013711.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2830_CR93","doi-asserted-by":"crossref","unstructured":"Kotoula V, Webster T, Stone J, Mehta MA. Resting-state connectivity studies as a marker of the acute and delayed effects of subanaesthetic ketamine administration in healthy and depressed individuals: a systematic review. Brain Neurosci Adv. 2021; 5: 23982128211055426.","DOI":"10.1177\/23982128211055426"},{"key":"2830_CR94","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.biopsych.2011.08.021","volume":"71","author":"WC Clapp","year":"2012","unstructured":"Clapp WC, Hamm JP, Kirk IJ, Teyler TJ. Translating long-term potentiation from animals to humans: a novel method for noninvasive assessment of cortical plasticity. Biol Psychiatry. 2012;71:496\u2013502.","journal-title":"Biol Psychiatry"},{"key":"2830_CR95","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1567-424X(09)70395-2","volume":"57","author":"J Classen","year":"2004","unstructured":"Classen J, Wolters A, Stefan K, Wycislo M, Sandbrink F, Schmidt A, et al. Paired associative stimulation. Suppl Clin Neurophysiol. 2004;57:563\u20139.","journal-title":"Suppl Clin Neurophysiol"},{"key":"2830_CR96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/03036758.2020.1780274","volume":"51","author":"IJ Kirk","year":"2020","unstructured":"Kirk IJ, Spriggs MJ, Sumner RL. Human EEG and the mechanisms of memory: investigating long-term potentiation (LTP) in sensory-evoked potentials. Journal of the Royal Society of New Zealand. 2020;51:24\u201340.","journal-title":"Journal of the Royal Society of New Zealand"},{"key":"2830_CR97","first-page":"45","volume":"5","author":"RL Sumner","year":"2020","unstructured":"Sumner RL, McMillan R, Spriggs MJ, Campbell D, Malpas G, Maxwell E, et al. Ketamine enhances visual sensory evoked potential long-term potentiation in patients with major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5:45\u201355.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2830_CR98","doi-asserted-by":"crossref","unstructured":"Skosnik PD, Sloshower J, Safi-Aghdam H, Pathania S, Syed S, Pittman B, et al. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. J Psychopharmacol. 2023: 2698811231179800.","DOI":"10.1177\/02698811231179800"},{"key":"2830_CR99","doi-asserted-by":"crossref","DOI":"10.1186\/s12868-024-00844-5","volume":"25","author":"RJ Murphy","year":"2024","unstructured":"Murphy RJ, Godfrey K, Shaw AD, Muthukumaraswamy S, Sumner RL. Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial. BMC Neurosci. 2024;25:7.","journal-title":"BMC Neurosci"},{"key":"2830_CR100","doi-asserted-by":"crossref","unstructured":"Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. 2021;11:929\u201342.","DOI":"10.1016\/j.tips.2021.08.003"},{"key":"2830_CR101","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11:642\u201351.","journal-title":"Nat Rev Neurosci"},{"key":"2830_CR102","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jad.2015.06.033","volume":"186","author":"A Allen","year":"2015","unstructured":"Allen A, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G, et al. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J Affective Disord. 2015;186:306\u201311.","journal-title":"J Affective Disord"},{"key":"2830_CR103","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","volume":"111","author":"AM Becker","year":"2022","unstructured":"Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther. 2022;111:886\u201395.","journal-title":"Clin Pharmacol Ther"},{"key":"2830_CR104","first-page":"e20210298","volume":"45","author":"AT Caliman-Fontes","year":"2023","unstructured":"Caliman-Fontes AT, Leal GC, Correia-Melo FS, Paix\u00e3o CS, Carvalho MS, Jesus-Nunes AP, et al. Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. Trends Psychiatry Psychother. 2023;45:e20210298.","journal-title":"Trends Psychiatry Psychother"},{"key":"2830_CR105","doi-asserted-by":"crossref","unstructured":"de Almeida RN, de Menezes Galvao AC, da Silva FS, dos Santos Silva EA, Palhano-Fontes F, Maia-de-Oliveira JP, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Front Psychol. 10 2019, ArtID 1234 2019;10.","DOI":"10.3389\/fpsyg.2019.01234"},{"key":"2830_CR106","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S1461145712000545","volume":"16","author":"WC Duncan","year":"2013","unstructured":"Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2013;16:301\u201311.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2830_CR107","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/jcph.1573","volume":"60","author":"P Glue","year":"2020","unstructured":"Glue P, Medlicott NJ, Surman P, Lam F, Hung N, Hung CT. Ascending-dose study of controlled-release ketamine tablets in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2020;60:751\u20137.","journal-title":"J Clin Pharmacol"},{"key":"2830_CR108","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0269881119874457","volume":"34","author":"P Glue","year":"2020","unstructured":"Glue P, Neehoff S, Sabadel A, Broughton L, Le Nedelec M, Shadli S, et al. Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. J Psychopharmacol. 2020;34:267\u201372.","journal-title":"J Psychopharmacol"},{"key":"2830_CR109","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/2045125320922474","volume":"10","author":"P Glue","year":"2020","unstructured":"Glue P, Medlicott NJ, Neehoff S, Surman P, Lam F, Hung N, et al. Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. Ther Adv Psychopharm. 2020c;10:6.","journal-title":"Ther Adv Psychopharm"},{"key":"2830_CR110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","volume":"175","author":"MF Grunebaum","year":"2018","unstructured":"Grunebaum MF, Galfalvy HC, Choo T-H, Keilp JG, Moitra VK, Parris MS, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175:327\u201335.","journal-title":"Am J Psychiatry"},{"key":"2830_CR111","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bdi.12487","volume":"19","author":"MF Grunebaum","year":"2017","unstructured":"Grunebaum MF, Ellis SP, Keilp JG, Moitra VK, Cooper TB, Marver JE, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disorders. 2017;19:176\u201383.","journal-title":"Bipolar Disorders"},{"key":"2830_CR112","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1017\/S1461145713001119","volume":"17","author":"C Haile","year":"2014","unstructured":"Haile C, Murrough J, Iosifescu D, Chang L, Al Jurdi R, Foulkes A, et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17:331\u20136.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2830_CR113","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze F, Vizeli P, Ley L, M\u00fcller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2021;46:537\u201344.","journal-title":"Neuropsychopharmacology"},{"key":"2830_CR114","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","volume":"47","author":"F Holze","year":"2022","unstructured":"Holze F, Ley L, Muller F, Becker AM, Straumann I, Vizeli P, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022;47:1180\u20137.","journal-title":"Neuropsychopharmacology"},{"key":"2830_CR115","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.biopsych.2021.02.243","volume":"89","author":"MJY Kang","year":"2021","unstructured":"Kang MJY, Vazquez G. A pilot study: an open-label biomarker development of ketamine for unipolar refractory depression. Biol Psychiatry. 2021;89:S92\u2013S93.","journal-title":"Biol Psychiatry"},{"key":"2830_CR116","doi-asserted-by":"crossref","unstructured":"Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A. et al. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology. 2023.","DOI":"10.1038\/s41386-023-01607-2"},{"key":"2830_CR117","doi-asserted-by":"crossref","unstructured":"Linkovski O, Shen H, Zwerling J, Filippou-Frye M, Jo B, Cordell E et al. Effects of rapastinel (formerly GLYX-13) on serum brain-derived neurotrophic factor in obsessive-compulsive disorder. J Clin Psychiatry. 2018;79:5849.","DOI":"10.4088\/JCP.17l11824"},{"key":"2830_CR118","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.4088\/JCP.08m04659","volume":"70","author":"R Machado-Vieira","year":"2009","unstructured":"Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry. 2009;70:1662\u20136.","journal-title":"J Clin Psychiatry"},{"key":"2830_CR119","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jad.2020.11.011","volume":"280","author":"GC Medeiros","year":"2021","unstructured":"Medeiros GC, Greenstein D, Kadriu B, Yuan P, Park LT, Gould TD, et al. Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. J Affect Disord. 2021;280:136\u20139.","journal-title":"J Affect Disord"},{"key":"2830_CR120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ijnp\/pyy051","volume":"22","author":"L Park","year":"2019","unstructured":"Park L, Furey M, Nugent AC, Farmer C, Ellis J, Szczepanik J, et al. Neurophysiological changes associated with antidepressant response to ketamine not observed in a negative trial of scopolamine in major depressive disorder. Int J Neuropsychopharmacol. 2019;22:10\u201318.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2830_CR121","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/JCP.0000000000001396","volume":"41","author":"JM Rocha","year":"2021","unstructured":"Rocha JM, Rossi GN, de Lima Osorio F, Bouso JC, de Oliveira Silveira G, Yonamine M, et al. Effects of ayahuasca on the recognition of facial expressions of emotions in naive healthy volunteers: a pilot, proof-of-concept, randomized controlled trial. J Clin Psychopharmacol. 2021;41:267\u201374.","journal-title":"J Clin Psychopharmacol"},{"key":"2830_CR122","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.2271","volume":"28","author":"JK Rybakowski","year":"2013","unstructured":"Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol-Clin Exp. 2013;28:87\u201390.","journal-title":"Hum Psychopharmacol-Clin Exp"},{"key":"2830_CR123","volume":"13","author":"SB Vogt","year":"2023","unstructured":"Vogt SB, Ley L, Erne L, Straumann I, Becker AM, Klaiber A, et al. Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl Psychiatry. 2023;13:172.","journal-title":"Transl Psychiatry"},{"key":"2830_CR124","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s43440-020-00203-1","volume":"73","author":"M Wang","year":"2021","unstructured":"Wang M, Zhang B, Zhou Y, Wang C, Zheng W, Liu W, et al. Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis. Pharmacol Rep. 2021;73:594\u2013603.","journal-title":"Pharmacol Rep"},{"key":"2830_CR125","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/15622975.2019.1679391","volume":"21","author":"M Woelfer","year":"2020","unstructured":"Woelfer M, Li M, Colic L, Liebe T, Di X, Biswal B, et al. Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex. World J Biol Psychiatry. 2020;21:696\u2013710.","journal-title":"World J Biol Psychiatry"},{"key":"2830_CR126","volume":"9","author":"W Zheng","year":"2021","unstructured":"Zheng W, Zhou YL, Wang CY, Lan XF, Zhang B, Zhou SM, et al. Plasma BDNF concentrations and the antidepressant effects of six ketamine infusions in unipolar and bipolar depression. PeerJ. 2021;9:e10989.","journal-title":"PeerJ"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02830-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T19:40:56Z","timestamp":1737402056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02830-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":126,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2830"],"URL":"https:\/\/doi.org\/10.1038\/s41380-024-02830-z","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}